A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia

Delaina Walker-Batson, Sandra Curtis, Rajeshwari Natarajan, Jean Ford, Nina Dronkers, Eva Salmeron, Jenny Lai, D. Hal Unwin

Research output: Contribution to journalArticle

202 Citations (Scopus)

Abstract

Background and Purpose - A number of studies suggest that drugs which increase the release of norepinephrine promote recovery when administered late (days to weeks) after brain injury in animals. A small number of clinical studies have investigated the effects of the noradrenergic agonist dextroamphetamine in patients recovering from motor deficits following stroke. To determine whether these findings extend to communication deficits subsequent to stroke, we administered dextroamphetamine, paired with speech/language therapy, to patients with aphasia. Methods - In a prospective, double-blind study, 21 aphasic patients with an acute nonhemorrhagic infarction were randomly assigned to receive either 10 mg dextroamphetamine or a placebo. Patients were entered between days 16 and 45 after onset and were treated on a 3-day/4-day schedule for 10 sessions. Thirty minutes after drug/placebo administration, subjects received a 1-hour session of speech/language therapy. The Porch Index of Communicative Ability was used at baseline, at 1 week off the drug, and at 6 months after onset as the dependent language measure. Results - Although there were no differences between the drug and placebo groups before treatment (P=0.807), by 1 week after the 10 drug treatments ended there was a significant difference in gain scores between the groups (P=0.0153), with the greater gain in the dextroamphetamine group. The difference was still significant when corrected for initial aphasia severity and age. At the 6-month follow-up, the difference in gain scores between the groups had increased; however, the difference was not significant (P=0.0482) after correction for multiple comparisons. Conclusions - Administration of dextroamphetamine paired with 10 1-hour sessions of speech/language therapy facilitated recovery from aphasia in a small group of patients in the subacute period after stroke. Neuromodulation with dextroamphetamine, and perhaps other drugs that increase central nervous system noradrenaline levels, may facilitate recovery when paired with focused behavioral treatment.

Original languageEnglish (US)
Pages (from-to)2093-2097
Number of pages5
JournalStroke
Volume32
Issue number9
StatePublished - 2001
Externally publishedYes

Fingerprint

Dextroamphetamine
Aphasia
Amphetamine
Placebos
Language Therapy
Speech Therapy
Pharmaceutical Preparations
Stroke
Norepinephrine
Therapeutics
Central Nervous System Agents
Aptitude
Double-Blind Method
Brain Injuries
Infarction
Appointments and Schedules
Language
Communication

Keywords

  • Aphasia
  • Cerebrovascular disorders
  • Dextroamphetamine
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Walker-Batson, D., Curtis, S., Natarajan, R., Ford, J., Dronkers, N., Salmeron, E., ... Unwin, D. H. (2001). A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke, 32(9), 2093-2097.

A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. / Walker-Batson, Delaina; Curtis, Sandra; Natarajan, Rajeshwari; Ford, Jean; Dronkers, Nina; Salmeron, Eva; Lai, Jenny; Unwin, D. Hal.

In: Stroke, Vol. 32, No. 9, 2001, p. 2093-2097.

Research output: Contribution to journalArticle

Walker-Batson, D, Curtis, S, Natarajan, R, Ford, J, Dronkers, N, Salmeron, E, Lai, J & Unwin, DH 2001, 'A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia', Stroke, vol. 32, no. 9, pp. 2093-2097.
Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32(9):2093-2097.
Walker-Batson, Delaina ; Curtis, Sandra ; Natarajan, Rajeshwari ; Ford, Jean ; Dronkers, Nina ; Salmeron, Eva ; Lai, Jenny ; Unwin, D. Hal. / A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. In: Stroke. 2001 ; Vol. 32, No. 9. pp. 2093-2097.
@article{5a3e67f6c9244c2c92452884da6835dc,
title = "A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia",
abstract = "Background and Purpose - A number of studies suggest that drugs which increase the release of norepinephrine promote recovery when administered late (days to weeks) after brain injury in animals. A small number of clinical studies have investigated the effects of the noradrenergic agonist dextroamphetamine in patients recovering from motor deficits following stroke. To determine whether these findings extend to communication deficits subsequent to stroke, we administered dextroamphetamine, paired with speech/language therapy, to patients with aphasia. Methods - In a prospective, double-blind study, 21 aphasic patients with an acute nonhemorrhagic infarction were randomly assigned to receive either 10 mg dextroamphetamine or a placebo. Patients were entered between days 16 and 45 after onset and were treated on a 3-day/4-day schedule for 10 sessions. Thirty minutes after drug/placebo administration, subjects received a 1-hour session of speech/language therapy. The Porch Index of Communicative Ability was used at baseline, at 1 week off the drug, and at 6 months after onset as the dependent language measure. Results - Although there were no differences between the drug and placebo groups before treatment (P=0.807), by 1 week after the 10 drug treatments ended there was a significant difference in gain scores between the groups (P=0.0153), with the greater gain in the dextroamphetamine group. The difference was still significant when corrected for initial aphasia severity and age. At the 6-month follow-up, the difference in gain scores between the groups had increased; however, the difference was not significant (P=0.0482) after correction for multiple comparisons. Conclusions - Administration of dextroamphetamine paired with 10 1-hour sessions of speech/language therapy facilitated recovery from aphasia in a small group of patients in the subacute period after stroke. Neuromodulation with dextroamphetamine, and perhaps other drugs that increase central nervous system noradrenaline levels, may facilitate recovery when paired with focused behavioral treatment.",
keywords = "Aphasia, Cerebrovascular disorders, Dextroamphetamine, Stroke",
author = "Delaina Walker-Batson and Sandra Curtis and Rajeshwari Natarajan and Jean Ford and Nina Dronkers and Eva Salmeron and Jenny Lai and Unwin, {D. Hal}",
year = "2001",
language = "English (US)",
volume = "32",
pages = "2093--2097",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia

AU - Walker-Batson, Delaina

AU - Curtis, Sandra

AU - Natarajan, Rajeshwari

AU - Ford, Jean

AU - Dronkers, Nina

AU - Salmeron, Eva

AU - Lai, Jenny

AU - Unwin, D. Hal

PY - 2001

Y1 - 2001

N2 - Background and Purpose - A number of studies suggest that drugs which increase the release of norepinephrine promote recovery when administered late (days to weeks) after brain injury in animals. A small number of clinical studies have investigated the effects of the noradrenergic agonist dextroamphetamine in patients recovering from motor deficits following stroke. To determine whether these findings extend to communication deficits subsequent to stroke, we administered dextroamphetamine, paired with speech/language therapy, to patients with aphasia. Methods - In a prospective, double-blind study, 21 aphasic patients with an acute nonhemorrhagic infarction were randomly assigned to receive either 10 mg dextroamphetamine or a placebo. Patients were entered between days 16 and 45 after onset and were treated on a 3-day/4-day schedule for 10 sessions. Thirty minutes after drug/placebo administration, subjects received a 1-hour session of speech/language therapy. The Porch Index of Communicative Ability was used at baseline, at 1 week off the drug, and at 6 months after onset as the dependent language measure. Results - Although there were no differences between the drug and placebo groups before treatment (P=0.807), by 1 week after the 10 drug treatments ended there was a significant difference in gain scores between the groups (P=0.0153), with the greater gain in the dextroamphetamine group. The difference was still significant when corrected for initial aphasia severity and age. At the 6-month follow-up, the difference in gain scores between the groups had increased; however, the difference was not significant (P=0.0482) after correction for multiple comparisons. Conclusions - Administration of dextroamphetamine paired with 10 1-hour sessions of speech/language therapy facilitated recovery from aphasia in a small group of patients in the subacute period after stroke. Neuromodulation with dextroamphetamine, and perhaps other drugs that increase central nervous system noradrenaline levels, may facilitate recovery when paired with focused behavioral treatment.

AB - Background and Purpose - A number of studies suggest that drugs which increase the release of norepinephrine promote recovery when administered late (days to weeks) after brain injury in animals. A small number of clinical studies have investigated the effects of the noradrenergic agonist dextroamphetamine in patients recovering from motor deficits following stroke. To determine whether these findings extend to communication deficits subsequent to stroke, we administered dextroamphetamine, paired with speech/language therapy, to patients with aphasia. Methods - In a prospective, double-blind study, 21 aphasic patients with an acute nonhemorrhagic infarction were randomly assigned to receive either 10 mg dextroamphetamine or a placebo. Patients were entered between days 16 and 45 after onset and were treated on a 3-day/4-day schedule for 10 sessions. Thirty minutes after drug/placebo administration, subjects received a 1-hour session of speech/language therapy. The Porch Index of Communicative Ability was used at baseline, at 1 week off the drug, and at 6 months after onset as the dependent language measure. Results - Although there were no differences between the drug and placebo groups before treatment (P=0.807), by 1 week after the 10 drug treatments ended there was a significant difference in gain scores between the groups (P=0.0153), with the greater gain in the dextroamphetamine group. The difference was still significant when corrected for initial aphasia severity and age. At the 6-month follow-up, the difference in gain scores between the groups had increased; however, the difference was not significant (P=0.0482) after correction for multiple comparisons. Conclusions - Administration of dextroamphetamine paired with 10 1-hour sessions of speech/language therapy facilitated recovery from aphasia in a small group of patients in the subacute period after stroke. Neuromodulation with dextroamphetamine, and perhaps other drugs that increase central nervous system noradrenaline levels, may facilitate recovery when paired with focused behavioral treatment.

KW - Aphasia

KW - Cerebrovascular disorders

KW - Dextroamphetamine

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0034824559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034824559&partnerID=8YFLogxK

M3 - Article

C2 - 11546902

AN - SCOPUS:0034824559

VL - 32

SP - 2093

EP - 2097

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -